The Brigham and Women's Hospital, Inc.

Harvard College

Massachusetts Institute of Technology

Children's Medical Center Corporation

Jinjun Shi

Omid C Farokhzad

Ulrich Von Andrian

Robert Samuel Langer

Pamela A Basto

Matteo Iannacone

Frank Alexis

Elliott Ashley Moseman

Elena Tonti

Aude Thiriot

Robert S Langer

Bruce R Zetter

Xi Zhu

Mohammad Ariful Islam

Jun Wu

Robert Langer

Yingjie Xu

Xiaoding Xu

Yanlan Liu

Zeyu Xiao

Cristian Vilos

Alexander Votruba

Ashley Moseman

Compositions and methods for treating cancer that include administering a therapeutically effective amount of a tumor suppressor mRNA complexed with a delivery vehicle as described herein, e.g., a nanoparticle.

Restoration of tumor suppression using MRNA-based delivery system

This disclosure relates to nanoparticles comprising a core comprising a poly(ester amide) polymer comprising a repeating unit of Formula (Ia):  and a repeating unit of Formula (Ib):  wherein W, W, X, A, X, A, and Xare as described herein, a payload molecule within the core, and a surface layer comprising a targeting ligand that binds or reacts selectively with a receptor on the outside surface of a cell. Methods of making such nanoparticles, and methods of using such nanoparticles as drug delivery vehicles, are also provided.

Nanoparticles having poly(ester amide) polymer cores as drug delivery vehicles

Restoration of tumor suppression using mRNA-based delivery system

This invention relates to amphiphile-polymer particles comprising obtaining a first solution comprising a water-insoluble polymer, a payload and a first amphiphile in a water-miscible solvent; mixing the first solution with an aqueous second solution to form an aqueous composition comprising a particle comprising a water-insoluble polymeric core comprising the water-insoluble polymer; the payload; and the first amphiphile.

Amphiphile-polymer particles

Disclosed herein are microvessel endothelial cell surface markers and methods, compositions, agents, and kits relating to those surface markers.

Microvessel endothelial cell surface markers and uses thereof

Disclosed herein are genes which are differentially expressed in venule endothelial cells (V-ECs) compared to non-venule endothelial cells (NV-ECs) and methods and compositions relating to those genes. Also disclosed herein are methods of modulating the venuleness of an endothelial cell or microvessel, methods of modulating leukocyte trafficking, methods of modulating inflammation, methods of targeting agents to tissues based on their ability to bind to surface markers expressed in a microvessel (e.g., venules and non-venules), methods of identifying the venuleness of endothelial cells or microvessels, methods of identifying agents that modulate the venuleness of endothelial cells or microvessels, methods of identifying agents that target microvessels, methods for treating diseases associated with leukocyte trafficking, methods for treating inflammatory diseases, and compositions and kits for use in the methods.

Venule endothelial cell genes and uses thereof

A particle includes an aqueous core; a first amphiphilic layer surrounding the aqueous core; and a polymeric matrix surrounding the first amphiphilic layer.

Lipid-polymer hybrid particles

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.

Adjuvant incorporation in immunoanotherapeutics

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.

Targeting of antigen presenting cells with immunonanotherapeutics

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.

Adjuvant incorporation in immunonanotherapeutics

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. For example, the present invention describes nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.

Nicotine immunonanotherapeutics

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising such nanocarriers. The present invention provides methods of designing, manufacturing, and using such nanocarriers and pharmaceutical compositions thereof.

Immunonanotherapeutics that provide IGG humoral response without T-cell antigen

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. For example, the present invention nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof.

Growing community of inventors

Boston, MA, United States of America

Jinjun Shi